Form 4/A for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2022-01-13 00:00:00 ET · period of report 2021-12-14 · accession 0001127602-22-001454 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2022-01-13 | 2021-12-14 | BCRX | Gayer Charles K | Chief Commercial Off | A - Grant | $0.00 | +80.0K | 216.6K | +59% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-14 | A | A | 80,000 | $0.00 | 216,556 | D | — | — | (F1) The number of restricted stock units awarded to the reporting person on December 14, 2021 was overstated in the original Form 4 due to an administrative error. This amendment corrects the error and reflects the corrected amount of restricted stock units awarded to the reporting person on such date. |